We uncovered a role for SLC2A3 as a potential prognostic marker and immune therapeutic target in HNSCC via bioinformatics methods for the first time, and it suggested avenues for the precise treatment of patients with HNSCC. The gene discussed is SLC2A3; the disease is head and neck squamous cell carcinoma.